Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
55 hedge funds and large institutions have $128M invested in Regulus Therapeutics in 2014 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
18% more capital invested
Capital invested by funds: $109M → $128M (+$19.2M)
12% more funds holding
Funds holding: 49 → 55 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$3.02M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.63M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$924K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$645K |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$571K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$10.7M |
| 2 |
HM
HealthCor Management
New York
|
-$1.62M |
| 3 |
Goldman Sachs
New York
|
-$1.47M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$990K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$552K |
RGLS Hedge Fund Activity: Q1 2014 in Review
55 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2014, worth a combined $128M — up 18% from $109M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RGLS positions and 3 closed out — a net gain of 6 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was Abingworth, opening a new position worth an estimated $3.02M. The largest seller was Austin W. Marxe & David M. Greenhouse, cutting an estimated $10.7M.
- 55 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2014, up from 49 in Q4 2013.
- Funds reported $128M of Regulus Therapeutics stock for Q1 2014, up 18% quarter-over-quarter.
- 9 funds opened new Regulus Therapeutics positions in Q1 2014 and 3 closed out, a net change of +6 holders.
- The largest Regulus Therapeutics buyer in Q1 2014 was Abingworth, an estimated $3.02M added.
- The largest Regulus Therapeutics seller in Q1 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2014.